The role of cannabis and cannabinoids in pain management

Pain Management: A Practical Guide for Clinicians, Sixth Edition

Volumn , Issue , 2001, Pages 357-375

  Russo, Ethan B ^a  

^a Montana Neurobehavioral Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993031075     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (198)

1. Abrahamov, A., & Mechoulam, R. (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences, 56(23-24), 2097-2102.
2. Access to therapeutic marijuana/cannabis. (1996). American Journal of Public Health, 86, 441-442.
3. Alosetron (Lotronex) for the treatment of irritable bowel syndrome. (2000). Medical Letters, 42(1081), 53-54.
4. Aulde, J. (1890). Studies in therapeutics-Cannabis indica. Therapeutic Gazette, 14, 523-526.
5. Azorlosa, J.L., Greenwald, M.K., & Stitzer, M.L. (1995). Marijuana smoking: Effects of varying puff volume and breathhold duration. Journal of Pharmacology and Experimental Therapeutics, 272(2), 560-569.
6. Barinaga, M. (1992). Pot, heroin unlock new areas for neuroscience. Science, 258, 1882-1884.
7. Barrett, M.L., Scutt, A M., & Evans, F.J. (1986). Cannflavin A and B, prenylated flavones from Cannabis sativa L. Experientia, 42(4), 452-453.
8. Batho, R. (1883, May 26). Cannabis indica. British Medical Journal, 1, 1002.
9. Behbehani, M.M. (1995). Functional characteristics of the midbrain periaqueductal gray. Progress in Neurobiology, 46(6), 575-605.
10. Benet, S. (1975). Early diffusion and folk uses of hemp. In V. Rubin (Ed.), Cannabis and Culture (pp. 39-49). The Hague: Mouton Publishers.
11. Biruni, M.I.A., & Said, H.M. (1973). al-Biruni’s book on pharmacy and materia medica. Karachi: Hamdard Academy.
12. Boger, D.L., Patterson, J.E., & Jin, Q. (1998). Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide. Proceedings, National Academy of Science (USA), 95(8), 4102-4107.
13. Brazis, M.Z., & Mathre, M.L. (1997). Dosage and administration of cannabis. In M.L. Mathre (Ed.), Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana (pp. 142-156). Jefferson, NC: McFarland.
14. Brenneisen, R. (1984). Psychotrope Drogen. II. Bestimmung der Cannabinoide in Cannabis sativa L. und in Cannabisprodukten mittels Hochdruckflüssigkeitschromatographie (HPLC) [Psychotropic drugs. II. Determination of cannabinoids in Cannabis sativa L. and in cannabis products with high pressure liquid chromatography (HPLC)]. Pharmaceutica Acta Helvetiae, 59(9-10), 247-59.
15. Brenneisen, R. (2001, in press). Pharmacokinetics. In F. Grotenhermen & E.B. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicity and therapeutic potential. Binghamton, NY: Haworth Press.
16. Brenneisen, R., Egli, A., Elsohly, M.A., Henn, V., & Spiess, Y. (1996). The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. International Journal of Clinical Pharmacology and Therapeutics, 34(10), 446-452.
17. British Medical Association (1997). Therapeutic uses of cannabis.Amsterdam: Harwood Academic Publishers.
18. Brown, J. (1883). Cannabis indica: A valuable remedy in menorrhagia. British Medical Journal, 1(May 26), 1002.
19. Burstein, S. (1992). Eicosanoids as mediators of cannabinoid action. In L. Murphy & A. Bartke (Eds.), Marijuana/cannabinoids: Neurobiology and neurophysiology of drug abuse. I. (pp. 73-91). Boca Raton, FL: CRC Press.
20. Burstein, S.H. (2000). Ajulemic acid (CT3): A potent analog of the acid metabolites of THC. Current Pharmaceutical Design, 6(13), 1339-1345.
21. Burstein, S.H. (2001, in press). The therapeutic potential of ajulemic acid (CT3). In F. Grotenhermen & E.B. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential. Binghamton, NY: Haworth Press.
22. Burstein, S., Levin, E., & Varanelli, C. (1973). Prostaglandins and cannabis. II. Inhibition of biosynthesis by the naturally occurring cannabinoids. Biochemical Pharmacology, 22(22), 2905-2910.
23. Burstein, S., Varanelli, C., & Slade, L. (1975). Prostaglandins and cannabis. III. Inhibition of biosynthesis by essential oil components of marihuana. Biochemical Pharmacology, 24(9), 1053-1054.
24. Calhoun, S.R., Galloway, G.P., & Smith, D.E. (1998). Abuse potential of dronabinol (Marinol). Journal of Psychoactive Drugs, 30(2), 187-196.
25. Calignano, A., La Rana, G., Giuffrida, A., & Piomelli, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394(6690), 277-281.
26. Carta, G., Gessa, G.L., & Nava, F. (1999). Dopamine D(2) receptor antagonists prevent delta(9)-tetrahydrocannabinolinduced antinociception in rats. European Journal of Pharmacology, 384(2-3), 153-156.
27. Carter, W.E., Coggins, W J., & Doughty, P.L. (1976). Chronic cannabis use in Costa Rica: A report by the Center for Latin American Studies of the University of Florida to the National Institute on Drug Abuse. Gainesville: University of Florida Press.
28. Chomel, P.J.B. (1782). Abrégé de l’histoire des plantes usuelles.Paris: Libraires Associés.
29. Chopra, I.C., & Chopra, R.W. (1957). The use of cannabis drugs in India. Bulletin on Narcotics, 9, 4-29.
30. Christison, A. (1851). On the natural history, action, and uses of Indian hemp. Monthly Journal of Medical Science of Edinburgh, Scotland, 13, 26-45, 117-121.
31. Cichewicz, D.L., Martin, Z.L., Smith, F.L., & Welch, S.P. (1999). Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: Dose-response analysis and receptor identification. Journal of Pharmacology and Experimental Therapeutics, 289(2), 859-67.
32. Clarke, R.C. (1998). Hashish! Los Angeles, CA: Red Eye Press
33. Clarke, R.C. (1981). Marijuana botany: An advanced study: The propagation and breeding of distinctive cannabis. Berkeley, CA: And/Or Press.
34. Clendinning, J. (1843). Observation on the medicinal properties of Cannabis sativa of India. Medico-Chirurgical Transactions, 26, 188-210.
35. Conrad, C. (1997). Hemp for health: The medicinal and nutritional uses of Cannabis sativa. Rochester, VT: Healing Arts Press.
36. Dastur, J.F. (1962). Medicinal plants of India and Pakistan.Bombay: D.B. Taraporevala Sons.
37. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946-1949.
38. Dioscorides, P. (1968). The Greek herbal of Dioscorides. London: Hafner Publishing.
39. Dixon, W.E. (1899). The pharmacology of Cannabis indica. British Medical Journal, 2, 1354-1357.
40. Donovan, M. (1845). On the physical and medicinal qualities of Indian hemp (Cannabis indica); With observations on the best mode of administration, and cases illustrative of its powers. Dublin Journal of Medical Science, 26, 368-402, 459-461.
41. Douthwaite, A.H. (1947). Choice of drugs in the treatment of duodenal ulcer. British Medical Journal, 43, 43-47.
42. Dreher, M.C. (1997). Cannabis and pregnancy. In M. L. Mathre (Ed.), Cannabis in medical practice: A legal, historical and pharmacological overview of the therapeutic use of marijuana (pp. 159-170). Jefferson, NC: McFarland.
43. Dwarakanath, C. (1965). Use of opium and cannabis in the traditional systems of medicine in India. Bulletin on Narcotics, 17, 15-19.
44. ElSohly, M.A., Little, T.L., Jr., Hikal, A., Harland, E., Stanford, D.F., & Walker, L. (1991). Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacology, Biochemistry, and Behavior, 40(3), 497-502.
45. ElSohly, M.A., Ross, S.A., Mehmedic, Z., Arafat, R., Yi, B., & Banahan, B.F., III (2000). Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Sciences, 45(1), 24-30.
46. Evans, A.T., Formukong, E.A., & Evans, F.J. (1987). Actions of cannabis constituents on enzymes of arachidonate metabolism: Anti-inflammatory potential. Biochemical Pharmacology, 36(12), 2035-2037.
47. Evans, F.J. (1991). Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Medica, 57(7), S60-S67.
48. Fan, P. (1995). Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion. Journal of Neurophysiology, 73, 907-910.
49. Farlow, J.W. (1889). On the use of belladonna and Cannabis indica by the rectum in gynecological practice. Boston Medical and Surgical Journal, 120, 507-509.
50. Ferri, S., Cavicchini, E., Romualdi, P., Speroni, E., & Murari, G. (1986). Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology, 89(2), 244-247.
51. Fettes, I., Gawel, M., Kuzniak, S., & Edmeads, J. (1985). Endorphin levels in headache syndromes. Headache, 25(1), 37-39.
52. Fimiani, C., Liberty, T., Aquirre, A.J., Amin, I., Ali, N., & Stefano, G.B. (1999). Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins and Other Lipid Mediators, 57(1), 23-34.
53. Fishbein, M. (1942). Migraine associated with menstruation. Journal of the American Medical Association, 237, 326.
54. Formukong, E.A., Evans, A.T., & Evans, F.J. (1988). Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation, 12(4), 361-371.
55. Formukong, E.A., Evans, A.T., & Evans, F.J. (1989). The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. Journal of Pharmacy and Pharmacology, 41(10), 705-709.
56. Fride, E., & Mechoulam, R. (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology, 231(2), 313-314.
57. Fried, P.A. (in press). Pregnancy. In F. Grotenhermen & E. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential. Binghamton, NY: Haworth Press.
58. Gerritsen, M.E., Carley, W.W., Ranges, G.E., Shen, C.P., Phan, S.A., Ligon, G.F., & Perry, C.A. (1995). Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. American Journal of Pathology, 147(2), 278-292.
59. Ghalioungui, P. (1987). The Ebers papyrus: A new English translation, commentaries and glossaries. Cairo: Academy of Scientific Research and Technology.
60. Gieringer, D. (1996a). Waterpipe study. Bulletin of the Multidisciplinary Association for Psychedelic Studies, 6, 59-63.
61. Gieringer, D. (1996b). Why marijuana smoke harm reduction? Bulletin of the Multidisciplinary Association for Psychedelic Studies, 6, 64-66.
62. Gieringer, D. (in press). Medical use of cannabis: Experience in California. In F. Grotenhermen & E. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicology, & therapeutic potential. Binghamton, NY: Haworth Press.
63. Goadsby, P.J., & Gundlach, A.L. (1991). Localization of 3Hdihydroergotamine-binding sites in the cat central nervous system: Relevance to migraine. Annals of Neurology, 29(1), 91-94.
64. Grigor, J. (1852). Indian hemp as an oxytocic. Monthly Journal of Medical Sciences, 14, 124.
65. Grinspoon, L., & Bakalar, J.B. (1997). Marihuana, the forbidden medicine (Rev. & exp. ed). New Haven, CT: Yale University Press.
66. Grotenhermen, F. (in press a). Definitions and explanations. In F. Grotenhermen & E. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicology, & therapeutic potential. Binghamton, NY: Haworth Press.
67. Grotenhermen, F. (in press b). Practical hints. In F. Grotenhermen & E. Russo (Eds.), Cannabis and Cannabinoids: Pharmacology, toxicology, & therapeutic potential. Binghamton, NY: Haworth Press.
68. Gu, W., & Clarke, R.C. (1998). A survey of hemp (Cannabis sativa L.) use by the Hmong (Miao) of the China/Vietnam border region. Journal of the International Hemp Association, 5(1), 4-9.
69. Guyatt, G.H., Keller, J.L., Jaeschke, R., Rosenbloom, D., Adachi, J.D., & Newhouse, M.T. (1990). The n-of-1 randomized controlled trial: Clinical usefulness. Our threeyear experience. Annals of Internal Medicine, 112(4), 293-299.
70. Hamann, W., & di Vadi, P.P. (1999). Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet, 353(9152), 560.
71. Hampson, A.J., Bornheim, L.M., Scanziani, M., Yost, C.S., Gray, A.T., Hansen, B.M., Leonoudakis, D.J., & Bickler, P.E. (1998). Dual effects of anandamide on NMDA receptormediated responses and neurotransmission. Journal of Neurochemistry, 70(2), 671-676.
72. Hampson, A.J., Grimaldi, M., Axelrod, J., & Wink, D. (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings, National Academy of Science (USA), 95(14), 8268-8273.
73. Hare, H.A. (1887). Clinical and physiological notes on the action of Cannabis indica. Therapeutic Gazette, 2, 225-228.
74. Hare, H.A. (1922). A text-book of practical therapeutics, with especial reference to the application of remedial measures to disease and their employment upon a rational basis (18th ed.). Philadelphia: Lea & Febiger.
75. Herkenham, M.A. (1993). Localization of cannabinoid receptors in brain: Relationship to motor and reward systems. In S. G. Korman & J. D. Barchas (Eds.), Biological basis of substance abuse (pp. 187-200). London: Oxford University.
76. Hoechstetter, S.S. (1930). Effects of alcohol and cannabis during labor. Journal of the American Medical Association, 94(15), 1165.
77. Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H., Smith, B., Newton, M., & Evans, F. (1997). Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia, 52(5), 483-486.
78. Hollister, L.E. (1986). Health aspects of cannabis. Pharmacological Reviews, 38(1), 1-20.
79. Hollister, L.E. (2000). An approach to the medical marijuana controversy. Drug and Alcohol Dependency, 58(1-2), 3-7.
80. Hutchinson, H.W. (1975). Patterns of marihuana use in Brazil. In V. Rubin (Ed.), Cannabis and culture (pp. 173-183). The Hague: Mouton.
81. Indian Hemp Drugs Commission (1894). Report of the Indian Hemp Drugs Commission, 1893-94. Simla, India: Govt. Central Print. Office.
82. Jaggar, S.I., Hasnie, F.S., Sellaturay, S., & Rice, A.S. (1998). The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 76(1-2), 189-199.
83. Jaggar, S.I., Sellaturay, S., & Rice, A.S. (1998). The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyperreflexia associated with inflammation of the rat urinary bladder. Neuroscience Letters, 253(2), 123-126.
84. Jain, A.K., Ryan, J.R., McMahon, F.G., & Smith, G. (1981). Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. Journal of Clinical Pharmacology, 21(8-9 Suppl.), 320S-326S.
85. Julien, M.S. (1849). Chirugie chinoise-Substance anesthétique employée en Chine, dans le commencement du III-ième siecle de notre ère, pour paralyser momentanement la sensibilité. Comptes Rendus Hebdomadaires de l’Académie des Sciences, 28, 223-229.
86. Kahl, O. (1994). Sabur ibn Sahl: Dispensatorium parvum (al-Aarabadhin al-Saghir). Leiden, The Netherlands: E.J. Brill.
87. Kimura, T., Ohta, T., Watanabe, K., Yoshimura, H., & Yamamoto, I. (1998). Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biological and Pharmaceutical Bulletin, 21(3), 224-226.
88. Klein, T.W., Friedman, H., & Specter, S. (1998). Marijuana, immunity and infection. Journal of Neuroimmunology, 83(1-2), 102-115.
89. Ko, M.C., & Woods, J. H. (1999). Local administration of delta9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: A peripheral cannabinoid action. Psychopharmacology (Berlin), 143(3), 322-326.
90. Kumar, A.M., Haney, M., Becker, T., Thompson, M L., Kream, R.M., & Miczek, K. (1990). Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Research, 525(1), 78-83.
91. Larson, E.B. (1990). N-of-1 clinical trials. A technique for improving medical therapeutics. West Journal of Medicine, 152(1), 52-56.
92. Lewis, B., Menage, V.L., Pellat, C.H., & Schacht, J. (1971). The encyclopedia of Islam. Leiden, The Netherlands: E.J. Brill.
93. Li, J., Daughters, R.S., Bullis, C., Bengiamin, R., Stucky, M.W., Brennan, J., & Simone, D.A. (1999). The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain, 81(1-2), 25-33.
94. Lichtman, A.H., Cook, S.A., & Martin, B.R. (1996). Investigation of brain sites mediating cannabinoid-induced antinociception in rats: Evidence supporting periaqueductal gray involvement. Journal of Pharmacology and Experimental Therapeutics, 276(2), 585-593.
95. Lilly (1898). Lilly’s Handbook of Pharmacy and Therapeutics.Indianapolis: Lilly and Company.
96. Linné, C.A. (1772). Materia medica per regna tria naturae.Lipsiae et Erlangae: Wolfgang Waltherum.
97. Lozano Camara, I. (1990). Tres tratados arabes sobre el Cannabis indica: Textos para la historia del hachis en las sociedades islamicas, S. XIII-XVI. Madrid: Agencia Española de Cooperacion Internacional Instituto de Cooperación con el Mundo Arabe.
98. Mackenzie, S. (1887). Remarks on the value of Indian hemp in the treatment of a certain type of headache. British Medical Journal, 1, 97-98.
99. Mackenzie, S. (1894). Therapeutique médicale: De la valeur therapeutique speciale du chanvre indien dans certains états morbides. Semaine Médicale, 14, 399-400.
100. Mailleux, P., & Vanderhaeghen, J.J. (1992). Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neuroscience Letters, 148(1-2), 173-176.
101. Mailleux, P., & Vanderhaeghen, J.J. (1994). Delta-9-tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in the caudate-putamen. European Journal of Pharmacology, 267(1), R1-3.
102. Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collageninduced arthritis. Proceedings, National Academy of Science (USA), 97(17), 9561-9566.
103. Maneuf, Y.P., Nash, J.E., Crossman, A.R., & Brotchie, J.M. (1996). Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology, 308(2), 161-164.
104. Mannische, L. (1989). An ancient Egyptian herbal. Austin: University of Texas.
105. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J.J., Ramos, J.A., & Fuentes, J.A. (1998). Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Research, Molecular Brain Research, 55(1), 126-132.
106. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J.J., Ramos, J.A., & Fuentes, J.A. (1999). Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences, 20(7), 287-294.
107. Marcandier, M. (1758). Traité du chanvre. Paris: Chez Nyon.
108. Marcandier, M. (1764). Treatise on hemp. London: T. Becket and P. A. de Hondt.
109. Margolis, J.S., & Clorfene, R. (1969). A child’s garden of grass (The official handbook for marijuana users). North Hollywood, CA: Contact Books.
110. Martin, M.A. (1975). Ethnobotanical aspects of cannabis in Southeast Asia. In V. Rubin (Ed.), Cannabis and Culture (pp. 63-75). The Hague: Mouton Publishers.
111. Martin, S., Padilla, E., Ocete, M.A., Galvez, J., Jimenez, J., & Zarzuelo, A. (1993). Anti-inflammatory activity of the essential oil of Bupleurum fruticescens. Planta Medica, 59(6), 533-536.
112. Marx, J. (1990). Marijuana receptor gene cloned. Science, 249(4969), 624-626.
113. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., & Bonner, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284), 561-564.
114. Mattes, R.D., Engelman, K., Shaw, L.M., & Elsohly, M.A. (1994). Cannabinoids and appetite stimulation. Pharmacology, Biochemistry, and Behavior, 49(1), 187-195.
115. Mattison, J.B. (1891). Cannabis indica as an anodyne and hypnotic. St. Louis Medical and Surgical Journal, 61, 265-271.
116. Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990). Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. European Archives of Psychiatry and Clinical Neuroscience, 240(1), 1-4.
117. McPartland, J. (2001). Cannabis and eicosanoids: A review of molecular pharmacology. Journal of Cannabis Therapeutics, 1(1), 71-83
118. McPartland, J.M. (in press). Contaminants and adulterants in herbal cannabis. In F. Grotenhermen & E.B. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicology, & therapeutic potential. Binghamton, NY: Haworth Press.
119. McPartland, J M., & Mediavilla, V. (in press). Non-cannabinoids in cannabis. In F. Grotenhermen & E. B. Russo (Eds.), Cannabis and cannabinoids. Binghamton, NY: Haworth Press.
120. McPartland, J.M., & Pruitt, P.L. (1997). Medical marijuana and its use by the immunocompromised. Alternative Therapies in Health and Medicine, 3(3), 39-45.
121. McPartland, J.M., & Pruitt, P.L. (1999). Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. Alternative Therapies in Health and Medicine, 5(4), 57-62.
122. Mechoulam, R., & Ben-Shabat, S. (1999). From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: The ongoing story of cannabis. Natural Product Reports, 16(2), 131-143.
123. Mechoulam, R., & Feigenbaum, J.J. (1987). Toward cannabinoid drugs. In G. Ellis & G. West (Eds.), Progress in medicinal chemistry (pp. 159-207). Amsterdam: Elsevier Science.
124. Mechoulam, R., Fride, E., & Di Marzo, V. (1998). Endocannabinoids. European Journal of Pharmacology, 359, 1-18.
125. Meng, I.D., Manning, B.H., Martin, W.J., & Fields, H.L. (1998). An analgesia circuit activated by cannabinoids. Nature, 395(6700), 381-383.
126. Michel, L. (1880). Propriétés médicinales de l’Indian hemp ou du Cannabis indica. Montpellier Medical, 45, 103-116.
127. Mikuriya, T.H. (1997). Chronic migraine headache: Five cases successfully treated with marinol and/or illiciit cannabis. http://206.61.184.43/schaffer/hemp/migrn1.htm
128. Mikuriya, T.H., & Aldrich, M.R. (1988). Cannabis 1988. Old drug, new dangers. The potency question. Journal of Psychoactive Drugs, 20(1), 47-55.
129. Milstein, S.L., MacCannell, K., Karr, G., & Clark, S. (1975). Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. International Pharmacopsychiatry, 10(3), 177-182.
130. Müller-Vahl, K.R., Kolbe, H., Schneider, U., & Emrich, H.M. (1998). Cannabinoids: Possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatrica Scandinavica, 98(6), 502-506.
131. Musonda, C.A., & Chipman, J.K. (1998). Quercetin inhibits hydrogen peroxide (H2O2)-induced NF-kappaB DNA binding activity and DNA damage in HepG2 cells. Carcinogenesis, 19(9), 1583-1589.
132. Nalin, D.R., Levine, M.M., Rhead, J., Bergquist, E., Rennels, M., Hughes, T., O’Donnel, S., & Hornick, R.B. (1978). Cannabis, hypochlorhydria, & cholera. Lancet, 2(8095), 859-862.
133. New York (City). Mayor’s Committee on Marihuana, Wallace, G. B., & Cunningham, E. V. (1973). The marihuana problem in the city of New York. Metuchen, NJ: Scarecrow Reprint Corp.
134. Nicolodi, M. (1998). Painful and non-painful effects of low doses of morphine in migraine sufferers partly depend on excitatory amino acids and gamma-aminobutyric acid. International Journal of Clinical Pharmacology Research, 18(2), 79-85.
135. Nicolodi, M., Del Bianco, P.L., & Sicuteri, F. (1997). Modulation of excitatory amino acids pathway: A possible therapeutic approach to chronic daily headache associated with analgesic drug abuse. International Journal of Clinical Pharmacology Research, 17(2-3), 97-100.
136. Nicolodi, M., & Sicuteri, F. (1995). Exploration of NMDA receptors in migraine: Therapeutic and theoretic implications. International Journal of Clinical Pharmacology Research, 15(5-6), 181-189.
137. Nicolodi, M., & Sicuteri, F. (1998). Negative modultors [sic] of excitatory amino acids in episodic and chronic migraine: Preventing and reverting chronic migraine. International Journal of Clinical Pharmacology Research, 18(2), 93-100.
138. Nicolodi, M., Volpe, A.R., & Sicuteri, F. (1998). Fibromyalgia and headache. Failure of serotonergic analgesia and Nmethyl-D-aspartate-mediated neuronal plasticity: Their common clues. Cephalalgia, 18(Suppl. 21), 41-44.
139. Notcutt, W., Price, M., & Chapman, G. (1997). Clinical experience with nabilone for chronic pain. Pharmaceutical Sciences, 3, 551-555.
140. Noyes, R., Jr., & Baram, D.A. (1974). Cannabis analgesia. Comprehensive Psychiatry, 15(6), 531-535.
141. Noyes, R., Jr., Brunk, S.F., Avery, D.A.H., & Canter, A.C. (1975). The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology and Therapeutics, 18(1), 84-9.
142. Noyes, R., Jr., Brunk, S.F., Baram, D.A., & Canter, A. (1975). Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology, 15(2-3), 139-43.
143. Nunn, J. F. (1996). Ancient Egyptian medicine. Norman: University of Oklahoma Press.
144. O’Shaughnessy, W.B. (1838-1840). On the preparations of the Indian hemp, or gunjah (Cannabis indica); Their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of the Medical and Physical Society of Bengal, 71-102, 421-461.
145. Osler, W., & McCrae, T. (1915). The principles and practice of medicine. New York: Appleton and Company.
146. Parkinson, J., & Cotes, T. (1640). Theatrum botanicum: The theater of plants. London: Tho. Cotes.
147. Partridge, W.L. (1975). Cannabis and cultural groups in a Colombian municipio. In V. Rubin (Ed.), Cannabis and culture (pp. 147-172). The Hague: Mouton Publishers.
148. Perez-Reyes, M., Burstein, S.H., White, W.R., McDonald, S. A., & Hicks, R.E. (1991). Antagonism of marihuana effects by indomethacin in humans. Life Sciences, 48(6), 507-515.
149. Peroutka, S.J. (1990a). Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurologic Clinics, 8(4), 829-839.
150. Peroutka, S.J. (1990b). The pharmacology of current antimigraine drugs. Headache, 30(1 Suppl.), 5-11; discussion, 24-28.
151. Peroutka, S.J. (1997). Dopamine and migraine. Neurology, 49(3), 650-656.
152. Pertwee, R.G. (1997). Cannabis and cannabinoids: Pharmacology and rationale for clinical use. Pharmacetical Science, 3, 539-545.
153. Pliny (1951). Pliny: Natural history. Cambridge, MA: Harvard University.
154. Randall, R.C. (1991). Muscle spasm, pain & marijuana therapy. Washington, D.C.: Galen Press.
155. Raskin, N.H. (1988). Headache (2nd ed.). New York: Churchill Livingstone.
156. Remington, J.P., Wood, H.C., Sadtler, S.P., LaWall, C.H., Kraemer, H., & Anderson, J.F. (1918). The dispensatory of the United States of America (20th ed.). Philadelphia: J. B. Lippincott.
157. Rennie, S.J. (1886). On the therapeutic value of tinctura Cannabis indica in the treatment of dysentery, more particularly in its sub-acute and chronic forms. Indian Medical Gazette, 21, 353-354.
158. Reynolds, J.R. (1868). On some of the therapeutical uses of Indian hemp. Archives of Medicine, 2, 154-160.
159. Richardson, J.D., Aanonsen, L., & Hargreaves, K.M. (1998a). Antihyperalgesic effects of spinal cannabinoids. European Journal of Pharmacology, 345(2), 145-153.
160. Richardson, J.D., Aanonsen, L., & Hargreaves, K.M. (1998b). Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. Journal of Neuroscience, 18(1), 451-457.
161. Richardson, J.D., Kilo, S., & Hargreaves, K.M. (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 75(1), 111-119.
162. Rosenthal, E., Gieringer, D., & Mikuriya, T. (1997). Marijuana medical handbook: A guide to therapeutic use. Oakland, CA: Quick American Archives.
163. Rubin, V. (1976). Cross-cultural perspectives on therapeutic uses of cannabis. In S. Cohen & R. Stillman (Eds.), The therapeutic potential of marihuana (pp. 1-17). New York: Plenum Medical.
164. Rubin, V.D., & Comitas, L. (1975). Ganja in Jamaica: A medical anthropological study of chronic marihuana use. The Hague: Mouton.
165. Rumpf, G.E., & Beekman, E.M. (1981). The poison tree: Selected writings of Rumphius on the natural history of the Indies. Amherst: University of Massachusetts Press.
166. Russo, E.B. (1998). Cannabis for migraine treatment: The once and future prescription? An historical and scientific review. Pain, 76,(1-2), 3-8.
167. Russo, E.B., Macarah, C.M., Todd, C.L., Medora, R.S., & Parker, K.K. (2000). Pharmacology of the essential oil of hemp at 5HT1A and 5HT2a receptors. Poster, 41st Annual Meeting of the American Society of Pharmacognosy, Seattle, WA. Journal of Natural Products.
168. Russo, E.B. (2000). Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions.Binghamton, NY: Haworth Press.
169. Russo, E.B. (2001). Hemp for headache: An in-depth historical and scientific review of cannabis in migraine treatment. Journal of Cannabis Therapeutics, 1(2), 21-92.
170. Russo, E.B. (in press). Migraine: Indications for cannabis and THC. In F. Grotenhermen & E. B. Russo, E. B. Cannabis and cannabinoids. Binghamton, NY: Haworth Press.
171. Schaefer, C.F., Brackett, D.J., Gunn, C.G., & Dubowski, K.M. (1979). Decreased platelet aggregation following marihuana smoking in man. Journal, Oklahoma State Medical Association, 72(12), 435-436.
172. Sée, M.G. (1890). Usages du Cannabis indica dans le traitement des névroses et dyspepsies gastriques. Bulletin de l’Academie Nationale de Medecine, 3, 158-193.
173. Shen, M., Piser, T.M., Seybold, V.S., & Thayer, S.A. (1996). Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neuroscience, 16(14), 4322-4334.
174. Shen, M., & Thayer, S.A. (1999). Delta-9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Molecular Pharmacology, 55(1), 8-13.
175. Shoemaker, J.V. (1899). The therapeutic value of Cannabis indica. Texas Medical News, 8(10), 477-488.
176. Silver, A. (1870). On the value of Indian hemp in menorrhagia and dysmenorrhoea. Medical Times and Gazette, 2, 59-61.
177. Snyder, S.H. (1971). Uses of marijuana. New York: Oxford University Press.
178. Sofia, R.D., Nalepa, S.D., Harakal, J.J., & Vassar, H.B. (1973). Anti-edema and analgesic properties of delta9-tetrahydrocannabinol (THC). Journal of Pharmacology and Experimental Therapeutics, 186(3), 646-655.
179. Spadone, C. (1991). Neurophysiologie du cannabis [Neurophysiology of cannabis]. Encephale, 17(1), 17-22.
180. Stefanis, C.N., Dornbush, R.L., & Fink, M. (1977). Hashish: Studies of long-term use. New York: Raven Press.
181. Strangman, N.M., & Walker, J.M. (1999). Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. Journal of Neurophysiology, 82(1), 472-477.
182. Suckling, C. (1891). On the therapeutic value of Indian hemp. British Medical Journal, 2, 12.
183. Tambe, Y., Tsujiuchi, H., Honda, G., Ikeshiro, Y., & Tanaka, S. (1996). Gastric cytoprotection of the non-steroidal antiinflammatory sesquiterpene, beta-caryophyllene. Planta Meicad, 62(5), 469-470.
184. Tashkin, D.P. (2001, in press). Respiratory risks from marijuana smoking. In F. Grotenhermen & E. B. Russo (Eds.), Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential. Binghamton, NY: Haworth Press.
185. Tashkin, D.P., Reiss, S., Shapiro, B.J., Calvarese, B., Olsen, J.L., & Lodge, J.W. (1977). Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects. American Review of Respiratory Disease, 115(1), 57-65.
186. Tashkin, D.P., Simmons, M.S., Sherrill, D.L., & Coulson, A.H. (1997). Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age. American Journal of Respiratory and Critical Care Medicine, 155(1), 141-148.
187. Thompson, R.C. (1924). The Assyrian herbal. London: Luzac and Co.
188. Thompson, R.C. (1949). A dictionary of Assyrian botany. London: British Academy.
189. Turner, C.E., & Elsohly, M.A. (1981). Biological activity of cannabichromene, its homologs and isomers. Journal of Clinical Pharmacology, 21, 283S-291S.
190. Volfe, Z., Dvilansky, A., & Nathan, I. (1985). Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. International Journal of Clinical Pharmacology Research, 5(4), 243-246.
191. Walker, J.M., Hohmann, A.G., Martin, W.J., Strangman, N.M., Huang, S.M., & Tsou, K. (1999). The neurobiology of cannabinoid analgesia. Life Sciences, 65(6-7), 665-673.
192. Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K., & Sañudo-Peña, M.C. (1999). Pain modulation by the release of the endogenous cannabinoid anandamide. Proceedings, National Academy of Science (USA), 96(21), 12198-12203.
193. Waring, E. (1874). Practical Therapeutics. Philadelphia: Lindsay and Blackiston.
194. Welch, S.P., & Eads, M. (1999). Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Research, 848(1-2), 183-190.
195. Wiegant, V.M., Sweep, C.G., & Nir, I. (1987). Effect of acute administration of delta 1-tetrahydrocannabinol on betaendorphin levels in plasma and brain tissue of the rat. Experientia, 43(4), 413-415.
196. Wirtshafter, D. (1997). Nutritional value of hemp seed and hemp seed oil. In M. L. Mathre (Ed.), Cannabis in medical practice (pp. 181-191). Jefferson, NC: McFarland and Company.
197. Zias, J., Stark, H., Sellgman, J., Levy, R., Werker, E., Breuer, A., & Mechoulam, R. (1993). Early medical use of cannabis. Nature, 363(6426), 215.
198. Zimmer, L.E., & Morgan, J.P. (1997). Marijuana myths, marijuana facts: A review of the scientific evidence. New York: Lindesmith Center.